Ascendia

  MARKET NEWS

 

XOMA Acquires Royalty & Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) & Phase 2 Oncology Asset
ASLAN Pharmaceuticals Enters Strategic Licensing Deal With Zenyaku Kogyo for the Development & Commercialization of Eblasakimab
Spaulding Clinical Expands Services to Include ADME Clinical Trials
Sygnature Discovery Launches its LPS In Vivo Model to Profile Early Stage Anti-Inflammatory Drugs
Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil-Based Mango-Flavored Rapid Dissolve ED Product
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded US Patent

  FEATURED EDITORIAL

 

  COMPANY PROFILE

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence extends from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany, and France. Owen Mumford Pharmaceutical Services specialises in the design, development, and manufacture of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel That Received IND Approval

Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel That Received IND Approval

Ascendia Pharmaceuticals CEO Jim Huang, PhD, recently announced Ascendia’s patented Emulsol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for….

SCYNEXIS Announces Achievement of First Development Milestone of  Million Under Exclusive License Agreement With GSK

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement With GSK

SCYNEXIS, Inc. recently announced the achievement of a $25-million performance-based development milestone under its exclusive license agreement with GSK for….

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic

The Lubrizol Corporation recently announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows….

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

Eli Lilly and Company and DICE Therapeutics, Inc. recently announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company that leverages its proprietary….

Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma

Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma

Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

 

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 5 – Controlled Release
July 12 – Analytical Testing